Core Points - Radiopharm Theranostics Limited has successfully raised approximately A$35 million through a private placement of new shares at A$0.03 per share, with significant participation from institutional investors including Lantheus Holdings, Inc. [1][5][6] - The company will also conduct a Share Purchase Plan (SPP) to raise an additional A$5 million for existing eligible shareholders, maintaining the same terms as the placement [3][6]. Placement Details - The placement involves the issuance of approximately 1,167 million new fully paid ordinary shares, with Lantheus investing A$7.6 million, increasing its shareholding to 14.5% [5][6]. - Each placement subscriber will receive one free attaching option for every share subscribed, with an exercise price of A$0.039 and an expiration date of October 31, 2027 [2][10]. Use of Funds - The funds raised will be allocated as follows: A$6 million for drug manufacturing, A$34 million for clinical trials, and A$19 million for administration and working capital, extending the funding runway into 2027 [4][7][6]. Shareholder Approval - The second tranche of the placement, amounting to A$22.5 million, will require shareholder approval at an upcoming Extraordinary General Meeting (EGM) anticipated in early December 2025 [9][10].

Core Insights - CVS Pharmacy has successfully acquired select assets from Rite Aid, now serving over 9 million former Rite Aid and Bartell Drugs patients [1][2] - The acquisition includes 63 former Rite Aid and Bartell Drugs stores and the prescription files of 626 pharmacies across 15 states [2][4] - CVS Health has completed the conversion of these stores and is actively operating them [3] CVS Pharmacy's Strategy - The company aims to expand access to pharmacy care and enhance its retail presence in local communities [4] - CVS has distributed prescription files to nearby CVS locations, hired over 3,500 former Rite Aid employees, and invested in existing CVS locations for better service [4] Market Context - Rite Aid filed for Chapter 11 bankruptcy in May, following a previous restructuring that closed around 850 stores [5] - The company is in the process of selling its assets, with CVS, Walgreens, Albertsons, Kroger, and Giant Eagle among the bidders for its prescription files [5] Financial Performance - In the second quarter, CVS reported an 18% increase in same-store pharmacy sales, with prescription volumes up by 6% and retail script share reaching 27.8%, partly due to the closure of Rite Aid stores [6]

Core Insights - CVS Pharmacy has completed the acquisition of select Rite Aid and Bartell Drugs assets, enhancing its pharmacy services in the Pacific Northwest and serving millions of customers [1][2]. Expansion across the Pacific Northwest - CVS now operates 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon, and Washington [2]. - The company has acquired prescription files from 626 former Rite Aid and Bartell Drugs pharmacies across 15 states, allowing CVS to serve over nine million patients [2]. Recruitment and Investment to Support Pharmacy Operations - CVS has hired more than 3,500 former employees from Rite Aid and Bartell Drugs to maintain service standards and ensure timely prescription support [4]. - Targeted investments have been made in existing pharmacy locations to improve staff scheduling, recruitment, and training [4]. Transaction Finalised Following Bankruptcy Court Approval - The acquisition was approved by the US Bankruptcy Court for the District of New Jersey in May 2025, and the entire transaction was completed in under four months [6]. - The final store acquisitions were concluded on September 30, with locations in Bend, Oregon, and Bainbridge Island, Washington [6]. Key Factors in Acquisition Decisions - CVS prioritized convenience and access to essential prescriptions when selecting Rite Aid locations and prescription files for acquisition [7]. - Most CVS stores receiving transferred prescription files are within three miles of existing Rite Aid branches, with nearly half within one mile, minimizing disruption for affected patients and communities [7].

Core Insights - CVS Health has completed the acquisition of 63 Rite Aid stores in Idaho, Oregon, and Washington, along with prescription files across 15 states, serving over 9 million customers [2][3] - The acquisition follows Rite Aid's bankruptcy filing earlier this year, marking its second bankruptcy in less than two years [3] - By acquiring prescription files, CVS and other pharmacy chains avoided taking on additional debt from physical store locations during the bankruptcy proceedings [4] Company Operations - CVS is now operating 63 former Rite Aid and Bartell Drugs locations and has acquired prescription files from 626 former Rite Aid and Bartell Drugs pharmacies across 15 states [5] - The company has hired over 3,500 former Rite Aid and Bartell Drug employees as part of the acquisition and store conversions [5] Strategic Goals - CVS Health aims to expand access to pharmacy care and grow its retail footprint in local communities through this acquisition [6] - The company plans to leverage its innovative pharmacy care programs and exclusive store brand products to enhance customer experience for former Rite Aid and Bartell Drugs patients [6]

US pharmacy chain Rite Aid closes final stores https://t.co/iPMCe6W6yY ...

Core Points - Rite Aid has officially closed all its stores following its Chapter 11 bankruptcy filing, marking its second bankruptcy since October 2023 [1][7] - The company faced significant financial challenges exacerbated by changes in the retail and healthcare sectors, with a reported loss of $750 million in the previous fiscal year [2][7] - Rite Aid's website now only provides a service for former customers to find new pharmacies and request pharmacy records [3] Bankruptcy and Store Closures - Rite Aid filed for Chapter 11 bankruptcy in May 2023 and announced the closure of all its stores as part of its bankruptcy plan [1][4] - At its peak, Rite Aid operated thousands of stores, but by May 2023, it had reduced to 1,240 locations across 15 states [6] Transition of Services - The company entered into agreements to transition its pharmacy services and assets to other pharmacy chains, including CVS Pharmacy and Walgreens, ensuring a smooth transfer of customer prescriptions [4] - CEO Matt Schroeder emphasized the importance of maintaining uninterrupted pharmacy services for customers and preserving jobs for associates during the transition [2][4] Asset Sales - Rite Aid auctioned its in-house ice cream brand, Thirty Ice Cream, to Hilrod Holdings for $19.2 million, with the transaction approved by a federal judge [5] - The company had previously owned Thrifty PayLess, Inc., which was part of the assets sold during the bankruptcy process [5] Debt Situation - After emerging from bankruptcy in 2024, Rite Aid was reported to still have $2.5 billion in debt [8]

Core Insights - The company has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 75mCi in the Phase 1 'HEAT' clinical trial for patients with HER2-positive advanced solid tumors [1][2]. Group 1: Clinical Trial Progress - The Phase 1 'HEAT' trial is progressing rapidly, with initial dosing starting in June and the first cohort completed swiftly [2]. - The DSMC confirmed positive safety, pharmacokinetic, and biodistribution data from the first cohort treated with 30mCi of Lu177-RAD202, allowing the study to continue without modifications [2]. - The second cohort of patients is expected to be enrolled by Q4 2025 [2]. Group 2: Product Information - RAD202 is a proprietary single domain monoclonal antibody targeting HER2-positive expression in advanced solid tumors, which are prevalent in breast cancer and other solid tumors [4]. - Previous diagnostic studies have shown RAD202's clinical proof-of-concept, along with positive safety and biodistribution results [4]. Group 3: Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs [5]. - The company is listed on ASX (RAD) and NASDAQ (RADX) and has a pipeline that includes one Phase 2 and three Phase 1 trials across various solid tumor cancers [5].

Financial Data and Key Metrics Changes - The company reported an underlying EBITDA of $20 million for FY '25, with operating cash flow also at $20 million and reduced debt levels to $67.7 million [23][34] - The total FY '25 dividend was $1.45 per share, representing a gross fully imputed dividend of $2.01 per share, which is 47% of AFFO, aligning with the target payout ratio of 40% to 70% [21][34] Business Line Data and Key Metrics Changes - Radius Care operates 24 aged care homes and four retirement villages, focusing on high acuity aged residential care and health services [12][13] - The company acquired the 109-bed St. Elisa care home in Christchurch for just under $1.1 million, expected to contribute to earnings from the second half of FY '26 [14][15] - CBIZ Catering Limited, acquired in October 2024, contributed $4.1 million in revenue and $500,000 in EBITDA for the period from October 2024 to March 2025 [15][16] Market Data and Key Metrics Changes - Occupancy rates are currently over 95%, with the latest figure at 95.8% [13][32] - The company has expanded into in-home care services, addressing the needs of New Zealand's aging population [17] Company Strategy and Development Direction - The company is in growth mode, focusing on capital light acquisitions, revenue diversification, and extending home opportunities [14][20] - The updated capital management framework aims to support reinvestment in core operating assets while maintaining sustainable dividend growth [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for growth across key financial metrics in FY '26, including underlying EBITDA and AFFO [21][35] - The company anticipates strong trading performance, with an upgraded guidance for underlying EBITDA in the first half of FY '26 to be between $14 million and $16 million [33] Other Important Information - The company has a strong focus on staff training and well-being, with a Net Promoter Score of 74 for facility managers, indicating high employee engagement [26][28] - The company has developed RadPro, an operational template that supports resident-centric decision-making and continuous improvement [18][39] Q&A Session Summary Question: Can you provide more details on RadPro and its development? - RadPro is the operating system developed over 21 years, encompassing all aspects of operations, including staff education and efficiency tools. It is now being expanded into home care services and has potential for marketing outside New Zealand [38][40]

Financial Performance & Growth - The company reported a 39% profit growth [30] - Underlying EBITDA for 1H26 is projected to be $14 million to $16 million [30, 56] - Underlying EBITDA increased by 20% to $23.5 million from $19.5 million [43] - Underlying EBITDAR Per Care Bed increased by 13% to $27.9K from $24.7K [45] - Total FY25 cash dividend was 1.45cps, compared to 0.70cps in FY24 [45] Expansion & Acquisitions - Acquired St Allisa, a 109-bed care home, through a leaseback arrangement [24, 27, 30] - Acquired 51% of Cibus Catering Limited, resulting in a $4.1 million revenue uplift [30] - Pursuing capital-light expansion focused on new-build 100-bed care homes leased from private investors [28] Operational Efficiency & Staffing - Company-wide staff turnover decreased by 30% year-on-year, reaching a record low [48] - 86% of care homes audited in FY25 received 4-Year Certification [49] - Average occupancy is trending upwards, reaching approximately 95% [50] - The company acquired 920,000 shares for $280,000, with an average buyback price of 30.4cps [39, 40]

Core Insights - Radiopharm Theranostics is advancing its clinical pipeline with significant milestones, including FDA Fast Track Designation for RAD101 and clearance for higher dosing of RAD204 [3][5][6] - The company confirmed a cash runway extending through mid-2026, with a year-end cash balance of $29.12 million, up from $18.58 million the previous year [10][12] Program and Business Updates - RAD204, a nanobody targeting PD-L1, is on track for higher dosing at 60mCi of Lu177, with enrollment for the second cohort expected to complete soon [6] - RAD202, targeting HER2, has initiated its Phase 1 HEAT trial, with preliminary data anticipated by the end of 2025 [6] - The company has established supply agreements for key radioisotopes, enhancing its clinical trial capabilities [3][12] Financial Update - For the fiscal year ending June 30, 2025, net cash outflows from operating activities totaled $36.67 million, primarily due to research and development expenditures [10][12] - The company received $4.58 million for research and development tax incentives for the 2024 financial year [12]